Compare GSK plc (GSK) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares 3 7 Year Treasury Bond ETF — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while iShares 3 7 Year Treasury Bond ETF trades at $113.5 (market cap $16.72B). The key difference: GSK plc is far larger — about 5.5× iShares 3 7 Year Treasury Bond ETF's market cap, and GSK plc pays a 3.9% dividend while iShares 3 7 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and iShares 3 7 Year Treasury Bond ETF for 43 Days on average.
| GSK | IEI | |
|---|---|---|
Market Cap | $91.88B | $16.72B |
Volume | 7,730,529 | 3,963,319 |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $120.72 |
52-Week Low | $43.24 | $113.17 |
Typical Hold Time | 93 Days | 43 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
IEI trades at $113.49 with minimal daily movement, up 0.1%. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. Recent corporate actions include consistent dividend payments. The bond market environment, highlighted by rising Treasury yields, influences sentiment, with news pointing to volatility in interest rates affecting fixed-income related assets.
The outlook remains cautious due to bearish technical signals and macroeconomic pressures from rising yields. Investment opportunities include dividend consistency, but risks involve interest rate sensitivity and market volatility. A neutral to bearish stance is warranted pending clearer fundamental data or stabilization in bond markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
